Biotin could make MS worse
Posted: Tue Aug 11, 2020 2:13 am
Not good news for those on Biotin, but very interesting from the point of view of the pathogenesis research.
The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis
https://link.springer.com/content/pdf/1 ... 0907-5.pdf
Excerpt
Thus, whether HDB (high dose biotin) is efficacious in PMS and/or whether it causes relapses is uncertain at this time. Both issues are clinically relevant.
Many centers, including our own, have treated a sizable number of patients with HDB because it was considered to be low risk and potentially beneficial for patients with few therapeutic options. Reviewing electronic medical record data from our comprehensive MS clinic, 350 patients with a diagnosis of MS were prescribed HDB from August 2016 to June 2020. Considering the negative results of the SPI2 trial, along with at least some studies reporting increased risk of relapse or increased MRI activity, our clinical practice will likely shift away from routine use of HDB.
This is unfortunate given the lack of robustly effective treatment options for PMS that slow progression and/or reverse disability. We look forward to the results of ongoing studies of several novel strategies.
Edit: Second report about the same, this time in the lancet
https://www.sciencedirect.com/science/a ... kWsr_nSr1Q
The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis
https://link.springer.com/content/pdf/1 ... 0907-5.pdf
Excerpt
Thus, whether HDB (high dose biotin) is efficacious in PMS and/or whether it causes relapses is uncertain at this time. Both issues are clinically relevant.
Many centers, including our own, have treated a sizable number of patients with HDB because it was considered to be low risk and potentially beneficial for patients with few therapeutic options. Reviewing electronic medical record data from our comprehensive MS clinic, 350 patients with a diagnosis of MS were prescribed HDB from August 2016 to June 2020. Considering the negative results of the SPI2 trial, along with at least some studies reporting increased risk of relapse or increased MRI activity, our clinical practice will likely shift away from routine use of HDB.
This is unfortunate given the lack of robustly effective treatment options for PMS that slow progression and/or reverse disability. We look forward to the results of ongoing studies of several novel strategies.
Edit: Second report about the same, this time in the lancet
https://www.sciencedirect.com/science/a ... kWsr_nSr1Q